China Resources Double-Crane Pharmaceutical Co.Ltd(600062) announcement: the wholly-owned subsidiary Shuanghe Limin has received the notice of approval for supplementary application for clindamycin phosphate injection issued by the State Food and drug administration, and the drug has passed the evaluation of the consistency of quality and efficacy of generic drugs. Clindamycin phosphate is a derivative of clindamycin. It has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed to clindamycin under the action of alkaline phosphatase to show antibacterial activity. As a commonly used antibiotic in clinic, it is suitable for patients who are allergic to penicillin or should not use penicillin, and serious bacterial infections that cannot be treated by less toxic alternative drugs (such as erythromycin).
© China Stock Market News